Shanghai Henlius Biotech Co. Ltd.
Please contact Sales at: (212) 520-2765 or email [email protected]
Latest From Shanghai Henlius Biotech Co. Ltd.
Plus deals involving Astellas/Menarini, Maruho/Fortress Biotech, Zenas/Bristol Myers Squibb, Huadong Medicine/MC2 and more.
BeiGene, Junshi, Henlius are studying their PD-1, TIGIT and BTLA-targeting assets in US trials for the relatively less crowded indication of small cell lung cancer.
Henlius has successfully established the safety and preliminary efficacy of its ophthalmology-indicated bevacizumab biosimilar HLX04-O in Phase I/II trials.
Chinese player Shanghai Henlius Biotech has published unaudited financial results for the first three months of 2023, in the wake of its 2022 annual report.
- Large Molecule
- Other Names / Subsidiaries
- Fosun Pharma
- Henlius Biopharmaceuticals
- Shanghai Henlius Biotech, Inc.
- Taiwan Henlix Biotech Co., Ltd.
- Hengenix Biotech
All set! This article has been sent to email@example.com.
All fields are required. For multiple recipients, separate email addresses with a semicolon.